FSTX F-star Therapeutics, Inc.

F-star is a clinical-stage biopharmaceutical company with an advanced pipeline of multiple immuno-oncology programs dedicated to creating a paradigm-shift in cancer therapy.

As of 06/24/2022     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/06/2016
Outstanding shares:  21,557,771
Average volume:  596,549
Market cap:   $137,107,424
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Valuation   (See tab for details)
PE ratio:   -4.08
PB ratio:   1.56
PS ratio:   5.78
Return on equity:   -38.32%
Net income %:   -142.45%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy